View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Congratulations to Keynote Stéphane Bancel and Moderna for their #1 Disruptive Ranking by CNBC

  • May 13, 2015

  • Congratulations to Moderna’s Stephane Bancel, our PODD 2015 keynote and Dr Tal Zaks, featured speaker at Immuno-Oncology 360° for leading the #1 ranked disruptive company according to CNBC.

    “The third annual Disruptor 50 list, CNBC features private companies in 16 industries—from aerospace to financial services to cybersecurity to retail—whose innovations are revolutionizing the business landscape. These forward-thinking upstarts have identified unexploited niches in the marketplace that have the potential to become billion-dollar businesses, and they rushed to fill them. In the process, they are creating new ecosystems for their products and services. ”


    Stéphane Bancel, President and Founding CEO, Moderna Therapeutics

    President and Founding CEO, Stéphane Bancel will keynote the 2015 Partnership Opportunities in Drug Delivery Conference. Stéphane joined Moderna in the summer of 2011 when it was a one employee and one patent company, after Dr. Noubar Afeyan and the board described to him the technology behind messenger RNA Therapeutics™. He has assembled a world-class team and raised the company’s financing. Stéphane is named as an inventor on over 45 patent filings in the field of messenger RNA technology. These filings include claims covering a broad range of novel compositions and formulations as well as manufacturing and clinical methods in the fields of human and animal therapeutics, diagnostics and cell processing.


    Tal Zaks, MD, PhD, C​hief Medical Officer, Moderna Therapeutics



    Tal Zaks, MD, PhD, C​hief Medical Officer will address the IO Investment Landscape and Business Perspective at the 1st annual At Immuno-Oncology 360° along with Michael Schmidt, PhD, Director, Biotechnology, Leerink Partners, Mark Simon, Partner, Torreya Partners, and Robert Stein, MD, PhD, Chief Science Officer, Agenus, Inc.